Immunome to Present Phase 2 AL102 Desmoid Tumor Trial Results at ESMO 2024

Immunome, Inc., a biotechnology company listed on Nasdaq under the ticker symbol IMNM, is dedicated to pioneering targeted cancer therapies. Recently, Immunome announced its participation at the European Society of Medical Oncology (ESMO) Congress in Barcelona from September 13-17, 2024. The company will present a poster detailing the latest results from the RINGSIDE Phase 2 clinical trial of AL102, a promising treatment for desmoid tumors.

The Phase 3 segment of the RINGSIDE trial concluded its enrollment phase in February 2024. Immunome anticipates releasing the topline data for this trial in the latter half of 2025. After the ESMO Congress presentation, a copy of the poster will be accessible on Immunome’s official website in the “Events & Presentations” section.

The forthcoming poster presentation, titled "Updated Results of the RINGSIDE Phase 2 Trial and Open-Label Extension of AL102 for the Treatment of Desmoid Tumors," will be presented by Dr. Bernd Kasper of the Mannheim Cancer Center at Mannheim University Medical Center on September 14, 2024.

Immunome is a clinical-stage company that focuses on creating cutting-edge targeted oncology therapies aimed at enhancing cancer patient outcomes. The company’s pipeline features several innovative therapies, including AL102, which is a gamma secretase inhibitor currently undergoing a Phase 3 trial for desmoid tumors. Additionally, Immunome is advancing other notable candidates such as IM-1021, a ROR1 antibody-drug conjugate (ADC), and IM-3050, a FAP-targeted radioligand. The Investigational New Drug (IND) applications for IM-1021 and IM-3050 are expected to be submitted in early 2025.

Immunome's leadership team brings a wealth of experience in the development and commercialization of pioneering targeted cancer therapies, including ADCs. This expertise underpins the company's commitment to developing first-in-class and best-in-class targeted therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!